Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease

Atherosclerosis

Volumn 234, Issue 2, 2014, Pages 288-294

  Haraguchi, Yoko ^a   Toh, Ryuji ^a   Hasokawa, Minoru ^a   Nakajima, Hideto ^a   Honjo, Tomoyuki ^a   Otsui, Kazunori ^a   Mori, Kenta ^a   Miyamoto Sasaki, Maki ^a   Shinohara, Masakazu ^a   Nishimura, Kunihiro ^b   Ishida, Tatsuro ^a   Hirata, Ken ichi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Atherosclerosis; Cholesterol efflux capacity; High density lipoprotein; In stent restenosis; Myeloperoxidase; Paraoxonese 1; Vascular cell adhesion molecule 1

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; ARYLDIALKYLPHOSPHATASE; AUTACOID; BIOLOGICAL MARKER; CHOLESTEROL; PEROXIDASE; PON1 PROTEIN, HUMAN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CHEMISTRY; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; FOLLOW UP; GRANULOCYTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; UMBILICAL VEIN ENDOTHELIAL CELL; BLOOD; CELL CULTURE; CHI SQUARE DISTRIBUTION; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; RADIOGRAPHY; RECURRENT DISEASE; RISK; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CELLS, CULTURED; CHI-SQUARE DISTRIBUTION; CHOLESTEROL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION MEDIATORS; LINEAR MODELS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PEROXIDASE; PREDICTIVE VALUE OF TESTS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84900864073     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.03.009     Document Type: Article

References (30)

1. Kannel W.B. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 1985, 110:1100-1107.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
3. Berneis K.K., Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. JLipid Res 2002, 43:1363-1379.
4. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. NEngl J Med 2007, 357:1301-1310.
5. Rosenson R.S., Brewer H.B., Ansell B., Barter P., Chapman M.J., Heinecke J.W., et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation 2013, 128:1256-1267.
6. Nicholls S.J., Hazen S.L. Myeloperoxidase, modified lipoproteins, and atherogenesis. JLipid Res 2009, 50(Suppl.):S346-S351.
7. Undurti A., Huang Y., Lupica J.A., Smith J.D., DiDonato J.A., Hazen S.L. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. JBiol Chem 2009, 284:30825-30835.
8. Aviram M., Vaya J. Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion. Curr Opin Lipidol 2013, 24:339-344.
9. Graner M., James R.W., Kahri J., Nieminen M.S., Syvanne M., Taskinen M.R. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. JAm Coll Cardiol 2006, 47:2429-2435.
10. Tsuzura S., Ikeda Y., Suehiro T., Ota K., Osaki F., Arii K., et al. Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism 2004, 53:297-302.
11. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. JClin Invest 1955, 34:1345-1353.
12. Mehta N.N., Li R., Krishnamoorthy P., Yu Y., Farver W., Rodrigues A., et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis 2012, 224:218-221.
13. Pencina M.J., D'Agostino R.B., Steyerberg E.W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30:11-21.
14. Meuwese M.C., Stroes E.S., Hazen S.L., van Miert J.N., Kuivenhoven J.A., Schaub R.G., et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. JAm Coll Cardiol 2007, 50:159-165.
15. Heslop C.L., Frohlich J.J., Hill J.S. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. JAm Coll Cardiol 2010, 55:1102-1109.
16. Schindhelm R.K., van der Zwan L.P., Teerlink T., Scheffer P.G. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification?. Clin Chem 2009, 55:1462-1470.
17. Thomas E.L., Learn D.B., Jefferson M.M., Weatherred W. Superoxide-dependent oxidation of extracellular reducing agents by isolated neutrophils. JBiol Chem 1988, 263:2178-2186.
18. Inoue M., Suehiro T., Nakamura T., Ikeda Y., Kumon Y., Hashimoto K. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism 2000, 49:1400-1405.
19. Kanellakis P., Nestel P., Bobik A. Angioplasty-induced superoxide anions and neointimal hyperplasia in the rabbit carotid artery: suppression by the isoflavone trans-tetrahydrodaidzein. Atherosclerosis 2004, 176:63-72.
20. Schillinger M., Minar E. Restenosis after percutaneous angioplasty: the role of vascular inflammation. Vasc Health Risk Manag 2005, 1:73-78.
21. Terashima M., Ohashi Y., Azumi H., Otsui K., Kaneda H., Awano K., et al. Impact of NAD(P)H oxidase-derived reactive oxygen species on coronary arterial remodeling: a comparative intravascular ultrasound and histochemical analysis of atherosclerotic lesions. Circ Cardiovasc Interv 2009, 2:196-204.
22. Daugherty A., Dunn J.L., Rateri D.L., Heinecke J.W. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. JClin Invest 1994, 94:437-444.
23. Xu J., Xie Z., Reece R., Pimental D., Zou M.H. Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: role of NAD(P)H oxidase-derived superoxide and peroxynitrite. Arterioscler Thromb Vasc Biol 2006, 26:2688-2695.
24. Demirbag R., Sezen Y., Yesilay A.B., Bas M., Yildiz A., Guntekin U., et al. Paraoxonase and arylesterase activities in stent restenosis in bare metal stent. Coron Artery Dis 2011, 22:289-293.
25. Khera A.V., Cuchel M., de la Llera-Moya M., Rodrigues A., Burke M.F., Jafri K., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. NEngl J Med 2011, 364:127-135.
26. Patel P.J., Khera A.V., Jafri K., Wilensky R.L., Rader D.J. The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. JAm Coll Cardiol 2011, 58:2068-2075.
27. Huang Y., Didonato J.A., Levison B.S., Schmitt D., Li L., Wu Y., et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med 2014, 20:193-203.
28. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. JClin Invest 1998, 101:1581-1590.
29. Boudjeltia K.Z., Delporte C., Van Antwerpen P., Franck T., Serteyn D., Moguilevsky N., et al. Myeloperoxidase-dependent LDL modifications in bloodstream are mainly predicted by angiotensin II, adiponectin, and myeloperoxidase activity: a cross-sectional study in men. Mediators Inflamm 2013, 2013:750742.
30. Efrat M., Rosenblat M., Mahmood S., Vaya J., Aviram M. Di-oleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: invitro and invivo studies. Atherosclerosis 2009, 202:461-469.